US drugmaker Ligand Pharmaceuticals (Nasdaq: LGND) has entered into commercial license and supply agreements with Marinus Pharmaceuticals (Nasdaq: MRNS), granting rights to use Ligand’s Captisol in the formulation of its intravenous (IV) ganaxolone.
Captisol is a patent protected, chemically-modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Marinus is preparing to initiate clinical trials with Captisol-enabled ganaxolone IV in patients with postpartum depression (PPD) and status epilepticus (SE).
This accord replaces the prior research agreement signed in 2014 which allowed Marinus to evaluate ganaxolone IV with Captisol in preclinical and Phase I clinical studies. Under this new deal, Marinus receives exclusive worldwide rights to Captisol-enabled ganaxolone for use in humans. In addition to an upfront payment, Ligand is entitled to potential milestone payments, royalties and revenue from future sales of Captisol-enabled ganaxolone.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze